Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 3/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2665081 | 0.96 | GCGR (0.49) | GCGRBCL2L1MCL1SERPINE1CYP2D6 | |
| SCHEMBL2647381 | 0.94 | GCGR (0.48) | GCGRBCL2L1MCL1SERPINE1CYP2D6 | |
| SCHEMBL2653731 | 0.92 | HAO1 (0.46) | GCGRBCL2L1MCL1CYP2D6HAO1 | |
| SCHEMBL2647125 | 0.89 | CYP2D6 (0.45) | GCGRBCL2L1MCL1CYP2D6GLP1R | |
| SCHEMBL2660761 | 0.88 | GCGR (0.43) | GCGRBCL2L1MCL1SERPINE1CYP2D6 | |
| SCHEMBL2655420 | 0.88 | PPARD (0.47) | GCGRCYP2D6GIPRGLP1R | |
| SCHEMBL2654474 | 0.87 | HAO1 (0.42) | GCGRBCL2L1MCL1CYP2D6HAO1 | |
| SCHEMBL2647568 | 0.86 | GCGR (0.45) | GCGRCYP2D6HAO1 | |
| SCHEMBL2660182 | 0.86 | GCGR (0.45) | GCGRCYP2D6HAO1 | |
| SCHEMBL2646694 | 0.85 | GCGR (0.49) | GCGRCYP2D6HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885BCL2L1 1470/4885MCL1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.